


I hereby certify that this correspondence is being deposited with the United States Postal Service in first class mail in an envelope addressed to:  
Assistant Commissioner for Patents,  
Washington, D.C. 20231 on 13 May 2003



1638  
Patent Application  
Docket No. KAS-103XC1  
Serial No. 09/918,740

  
Jeff Lloyd, Patent Attorney

RECEIVED  
MAY 16 2003  
TECH CENTER 1600/2900

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

Examiner : David H. Kruse, Ph.D.  
Art Unit : 1638  
Applicant(s) : Frederick M. Hahn, Adelheid R. Kuehnle  
Serial No. : 09/918,740  
Filed : July 31, 2001  
For : Manipulation of Genes of the Mevalonate Isoprenoid Pathways to Create Novel Traits in Transgenic Organisms

Assistant Commissioner for Patents  
Washington, D.C. 20231

SECOND SUPPLEMENTAL INFORMATION DISCLOSURE STATEMENT  
UNDER 37 CFR §§1.97 AND 1.98

Sir:

In accordance with 37 CFR §1.56, the references listed on the attached form PTO-1449 are being brought to the attention of the Examiner for consideration in connection with the examination of the above-identified patent application. Copies of the cited documents are enclosed.

The undersigned hereby certifies that the items of information contained in this statement were cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this statement.


Applicants respectfully assert that the substantive provisions of 37 CFR §§1.97 and 1.98 are met by the foregoing statements.

Respectfully submitted,

  
Jeff Lloyd  
Patent Attorney

Registration No. 35,589  
Phone No.: 352-375-8100  
Fax No.: 352-372-5800  
Address : 2421 N.W. 41st Street, Suite A-1  
Gainesville, FL 32606-6669

JL/srp  
Enclosures as stated above



PTO/SB/08A (10-01)  
Approved for use through 10/31/2002. OMB 0651-0031  
U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Complete if Known**

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Sheet

1

of

2

Application Number

09/918,740

Filing Date

July 31, 2001

First Named Inventor

Frederick M. Hahn

Art Unit

1638

Examiner Name

David H. Kruse, Ph.D.

Attorney Docket Number

KAS-103XC1

**U.S. PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number - Kind Code <sup>2</sup> (if known)			
	U1	US-5,545,816	8/13/1996	Ausich <i>et al.</i>	throughout
	U2	US-			
	U3	US-			
	U4	US-			
	U5	US-			
	U6	US-			
	U7	US-			
	U8	US-			
	U9	US-			
	U10	US-			
	U11	US-			
	U12	US-			
	U13	US-			
	U14	US-			
	U15	US-			
	U16	US-			
	U17	US-			
	U18	US-			
	U19	US-			
	U20	US-			

**FOREIGN PATENT DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> - Number <sup>4</sup> - Kind Code <sup>5</sup> (if known)				
	F1					
	F2					
	F3					
	F4					
	F5					
	F6					
	F7					
	F8					
	F9					
	F10					


Examiner  
Signature

Date  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> See Kind Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.



PTO/SB/08B (10-01)

Approved for use through 10/31/2002. OMB 0651-0031

U.S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449B/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)

Complete if Known

Application Number	09/918,740
Filing Date	July 31, 2001
First Named Inventor	Frederick M. Han
Group Art Unit	1638
Examiner Name	David H. Kruse, PH.D.
Attorney Docket Number	KAS-103XC1

Sheet 2 of 2

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article, (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	R1	SANDRINE CHAMPENOY <i>et al.</i> , "Expresison of the yeast mevalonate kinase gene in transgenic tobacco" Molecular Breeding (1998) 4:291-300.	
	R2	IGNACIO E. MALDONADO-MENDOZA <i>et al.</i> , Molecular Characterization of three differentially expressed members of the <i>Camptotheca acuminata</i> 3-hydroxy-3-methylglutaryl CoA reductase (HMGR) gene family, Plant Molecular Biology (1997) 34:781-790.	
	R3	MICHEL ROMER, Isoprenoid biosynthesis via the mevalonate-independent route, a novel target for antibacterial drugs? Progress in Drug Research (1998) 50:137-154.	
	R4	K. SHINOZAKI <i>et al.</i> , The complete nucleotide sequence of the tobacco chloroplast genome: its gene organization and expression, EmboJournal (1986) 5(9):2043-2049.	
	R5	FRANK THOMAS <i>et al.</i> , Expression of the rp123, and rps19 genes in spinach chloroplasts, Nucleic Acids Resarch (1988) 16:2461-2472.	
	R6		
	R7		
	R8		
	R9		
	R10		
	R11		
	R12		
	R13		

Examiner  
SignatureDate  
Considered

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Applicant's unique citation designation number (optional). <sup>2</sup> Applicant is to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending on the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.